Trials / Unknown
UnknownNCT01719874
Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza
A Phase 2a, Double-Blind, Placebo-Controlled Study TCN 032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Subjects Challenged With H3N2 Influenza A Virus
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Theraclone Sciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety and efficacy of TCN-032 given to healthy adult volunteers that have been inoculated with the influenza A virus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TCN-032 | |
| BIOLOGICAL | Placebo (saline) |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2012-12-01
- Completion
- 2013-03-01
- First posted
- 2012-11-01
- Last updated
- 2012-11-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01719874. Inclusion in this directory is not an endorsement.